Monday, October 29, 2012

An Example of Do Harm: Pfizer and Trovafloxacin


File:Trovafloxacin.png


     In follow up to our class discussions of clinical trials in foreign countries, I thought it might be interesting to mention the existence of more illegal examples of drug testing.  In reading about certain instances of abuse by pharmaceutical companies, I was horrorstruck by the basic disregard for human rights and health, especially considering the medical purpose of the studies.  Clearly, the business aspect of big pharm has been able to trump the do-no-harm ideology of medicine in numerous cases.
     One such example is the 1996 testing of Trovafloxacin, a quinolone antibiotic used to treat meningitis, on 100 children in Nigeria.  All of the children treated with the drug were already severely ill with meningitis.  Of the 200 children in the study, 100 received the untested Trovafloxacin while the other 100 received Cetriaxone (1).  Five children on Trovafloxacin died due to the drug, with many others suffering from physical disabilities including paralysis, deafness slurred speech and loss of sight.  Other children suffered from brain damage.  It was also shown that in at least one case, a child receiving Trovafloxacin was kept on the drug despite her deteriorating condition, a breach of experimental ethics.  This child died as a result.
    Six children in the Cetriaxone control group also died, despite this drug being an excepted form of treatment for meningitis.  It was later shown that this was a result of Pfizer deliberately providing its subjects with less than the proper dose of medication.  I imagine this was to cut costs of the study.  Amazingly, the study was conducted without the permission of the Nigerian government and without the consent of the children's' parents.
     Also amazing were the company's attempts to bribe and pressure government officials to drop charges after the crime had been found out and the numerous cover-ups that have taken place (3).
   Terrifyingly, according to expert Charles Medawar, director of Social Audit, the UK pressure group that monitors the pharmaceutical industry, “This particular case looks to be very bad, but I hardly think it is untypical.”


1. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1119465/
2. http://www.irinnews.org/PrintReport.aspx?ReportId=72601
3. http://www.guardian.co.uk/business/2010/dec/09/wikileaks-cables-pfizer-nigeria



No comments:

Post a Comment